UK Regulator Explains Data Requirements For Converted EU Approvals
New Portal Planned For Information Submission
In another of the many guidances it has issued on medicines regulation in the post-Brexit UK, the MHRA explains the additional information it will need from companies whose EU marketing authorizations are converted into national MAs in January 2021, and the new labeling requirements for those products.
You may also be interested in...
The Medicines and Healthcare products Regulatory Agency has outlined the various common scenarios that may occur when companies submit a UK pediatric investigation plan after the Brexit transition period has expired.
The Medicines and Healthcare products Regulatory Agency has put procedures in place to renew UK marketing authorizations that are grandfathered from the EU system after the Brexit transition period ends.
New UK guidance on the post-Brexit regulation of medicines says the Medicines and Healthcare products Regulatory Agency will be able to issue its own conditional marketing authorizations next year. The agency has also outlined how drug safety reports should be submitted.